Page 39 - Pharma Sector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Backed by growth in pharmaceutical, high tech, and consumer products sectors amid the Covid-19 pandemic, India is set to see a median increase in salaries of 7 per cent in 2021, the highest among key Asia Pacific markets, according to a survey. However, the average salary growth in 2021 is projected at 6.4 per cent. This is slightly lower than last year, when the median increase was 7.5 per cent and average was 5.9 per cent, the latest Salary Budget Planning Survey by Willis Towers Watson has found. Compiled by the NASDAQ-listed Willis Towers Watson’s Data Services Practice, the survey, ...

Read more about Indian pharma market expected to hit $130 billion by 2030: Sadananda Gowda on Business Standard. The Indian pharmaceutical industry has proved to be a dependable supplier of quality drugs in a time of global need on account of the COVID-19 pandemic, and is expected to reach a size of USD 130 billion by 2030,Chemical and Fertiliser Minister D V

Despite a 24 per cent hit on its US business, Ahmedabad-based Torrent Pharmaceuticals Ltd (TPL) registered an over 18 per cent growth in its consolidated net profit for the third quarter ended December 31, 2020. The company's consolidated net profit for the quarter was Rs 297 crore as against Rs 251 crore in the corresponding period last year. Not only did Torrent Pharma's US revenues fall by 24 per cent to Rs 292 crore, its India revenues grew in single digits of seven per cent to stand at Rs 930 crore in the quarter. As a result, the company's consolidated total revenue from operations f...

Drug firm Torrent Pharmaceuticals on Monday reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December. The company had posted a net profit of Rs 251 crore for the corresponding period of the previous fiscal, Torrent Pharma said in a filing to BSE. Consolidated revenue of the company stood at Rs 1,995 crore for the quarter under consideration. It was Rs 1,966 crore for the same period a year ago, it added. India revenues for the third quarter ended December 2020 was at Rs 930 crore, a growth of 7 per cent. Growth was driven by market r...

Drug firm AstraZeneca India on Monday said it has received marketing authorisation to use its anti-diabetic drug dapagliflozin for the treatment of patients with chronic kidney disease (CKD). The receipt of the permission paves way for the launch of dapagliflozin tablets (10 mg) in the country to treat CKD, the company said in a statement. The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with CKD, it added. The study results of dapagliflozin showed significant benefits in reducing CKD pr...